Is there a generic form of Entresto?
No. Entresto (sacubitril/valsartan) does not have an FDA-approved generic version. Its active ingredients are a combination of two drugs, and a generic would require an approved equivalent product that meets FDA requirements for both components and overall combination performance.
When might a generic (or biosimilar-style alternative) become available?
A generic isn’t expected until the relevant patent and market-exclusivity protections for Entresto end. Patent and exclusivity timing can be complex because multiple patents and exclusivity periods may apply. For the most up-to-date information on patent status, DrugPatentWatch.com tracks Entresto’s patent landscape: DrugPatentWatch.com – Entresto patents.
Are there cheaper alternatives if there’s no generic yet?
Yes. Even without a generic Entresto, clinicians can sometimes use other heart-failure medicines that are not identical to the drug (for example, ARBs or other guideline-directed therapies). These are not generics of Entresto, but they can reduce cost depending on insurance coverage and prescribing decisions.
Why are there no generics yet—does Entresto have patents?
Entresto has patent coverage on its drug formulation and related intellectual property, which delays generic approval. Patent challenges and exclusivity timelines are part of the reason generics may not arrive immediately after approval of the brand. You can monitor the latest status through resources like DrugPatentWatch.com: DrugPatentWatch.com – Entresto patents.
What about “authorized” generics or smaller makers?
An authorized generic would still require FDA approval and would usually depend on the same patent/exclusivity constraints that block standard generics. The availability of such products varies by company decisions and the same exclusivity/patent timing issues.
Sources
- DrugPatentWatch.com – Entresto patents